Filters
Term Search
You can select from the dropdown list OR enter your own terms to refine the search.
Last Updated: 10/31/2025
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Beamion BCGC-1: phase Ib/II trial of zongertinib for advanced HER2-positive breast or gastroesophageal cancers.
Journal: Future oncology (London, England)
Published: October 18, 2025
Nonclinical and Clinical Assessments of an Optimized Tablet Formulation of the Novel HER2-Selective Tyrosine Kinase Inhibitor Zongertinib: Focus on Relative Bioavailability and Impact of Variation of Gastric pH.
Journal: Molecular pharmaceutics
Published: October 08, 2025
Relative Bioavailability of Zongertinib, an Orally Administered HER2-Selective Tyrosine Kinase Inhibitor, under Fed and Fasted Conditions in Healthy Male Participants: Results from Two Randomized, Open-Label, Crossover Studies.
Journal: Molecular pharmaceutics
Published: October 08, 2025
Zongertinib (Hernexeos) for NSCLC.
Journal: The Medical letter on drugs and therapeutics
Published: September 22, 2025
Zongertinib.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: September 08, 2025
Targeted Therapy in HER2 Exon 20-Mutant Non-small Cell Lung Cancer With Leptomeningeal Disease: A Case-Based Approach to Treatment Decision-Making.
Journal: Cureus
Published: July 28, 2025
The development of Zongertinib for HER2-mutant NSCLC.
Journal: Critical reviews in oncology/hematology
Published: May 18, 2025
Promising results with zongertinib in advanced-stage HER2-mutant NSCLC.
Journal: Nature reviews. Clinical oncology
Published: May 13, 2025
HER2 in Non-Small Cell Lung Cancer (NSCLC): Evolution of the Therapeutic Landscape and Emerging Drugs-A Long Way to the Top.
Journal: Molecules (Basel, Switzerland)
Published: May 06, 2025
Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer.
Journal: The New England journal of medicine
Published: April 28, 2025
HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 03, 2025
Last Updated: 10/31/2025